Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96CB9
UPID:
NSUN4_HUMAN
Alternative names:
5-methylcytosine tRNA methyltransferase NSUN4; NOL1/NOP2/Sun domain family member 4
Alternative UPACC:
Q96CB9; A8K6S6; B3KQ50; B4DHA4; Q5TDF7; Q96AN8; Q9HAJ8
Background:
The 5-methylcytosine rRNA methyltransferase NSUN4 plays a crucial role in mitochondrial ribosome assembly. It is responsible for the methylation of mitochondrial 12S rRNA, a key process in the maturation of the mitochondrial ribosome small subunit (SSU). NSUN4's activity is independent of MTERFD2/MTERF4 but is targeted to the large subunit (LSU) by these proteins, ensuring the proper assembly of SSU and LSU. Additionally, NSUN4 can methylate 16S rRNA of the LSU in vitro, a process enhanced by MTERFD/MTERF4.
Therapeutic significance:
Understanding the role of 5-methylcytosine rRNA methyltransferase NSUN4 could open doors to potential therapeutic strategies.